Host signaling and EGR1 transcriptional control of human cytomegalovirus replication and latency.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
11 2019
Historique:
received: 11 05 2019
accepted: 21 08 2019
entrez: 15 11 2019
pubmed: 15 11 2019
medline: 5 3 2020
Statut: epublish

Résumé

Sustained phosphotinositide3-kinase (PI3K) signaling is critical to the maintenance of alpha and beta herpesvirus latency. We have previously shown that the beta-herpesvirus, human cytomegalovirus (CMV), regulates epidermal growth factor receptor (EGFR), upstream of PI3K, to control states of latency and reactivation. How signaling downstream of EGFR is regulated and how this impacts CMV infection and latency is not fully understood. We demonstrate that CMV downregulates EGFR early in the productive infection, which blunts the activation of EGFR and its downstream pathways in response to stimuli. However, CMV infection sustains basal levels of EGFR and downstream pathway activity in the context of latency in CD34+ hematopoietic progenitor cells (HPCs). Inhibition of MEK/ERK, STAT or PI3K/AKT pathways downstream of EGFR increases viral reactivation from latently infected CD34+ HPCs, defining a role for these pathways in latency. We hypothesized that CMV modulation of EGFR signaling might impact viral transcription important to latency. Indeed, EGF-stimulation increased expression of the UL138 latency gene, but not immediate early or early viral genes, suggesting that EGFR signaling promotes latent gene expression. The early growth response-1 (EGR1) transcription factor is induced downstream of EGFR signaling through the MEK/ERK pathway and is important for the maintenance of hematopoietic stemness. We demonstrate that EGR1 binds the viral genome upstream of UL138 and is sufficient to promote UL138 expression. Further, disruption of EGR1 binding upstream of UL138 prevents the establishment of latency in CD34+ HPCs. Our results indicate a model whereby UL138 modulation of EGFR signaling feeds back to promote UL138 gene expression and suppression of replication for latency. By this mechanism, the virus has hardwired itself into host cell biology to sense and respond to changes in homeostatic host cell signaling.

Identifiants

pubmed: 31725811
doi: 10.1371/journal.ppat.1008037
pii: PPATHOGENS-D-19-00882
pmc: PMC6855412
doi:

Substances chimiques

EGR1 protein, human 0
Early Growth Response Protein 1 0
Viral Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1008037

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI079059
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009213
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007472
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI021640
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI021640
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI127335
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI079059
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Int Rev Cell Mol Biol. 2015;314:1-41
pubmed: 25619714
J Virol. 1997 Jan;71(1):586-94
pubmed: 8985387
Methods Mol Med. 2002;63:123-41
pubmed: 21437804
J Gen Virol. 2008 Feb;89(Pt 2):359-68
pubmed: 18198366
J Immunol. 2010 Mar 15;184(6):3213-22
pubmed: 20173022
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W531-4
pubmed: 23620286
J Virol. 2017 Feb 14;91(5):
pubmed: 27974567
J Biol Chem. 2001 Jul 6;276(27):24531-9
pubmed: 11342553
J Immunol Methods. 2009 Aug 15;347(1-2):70-8
pubmed: 19567251
J Virol. 2018 Sep 26;92(20):
pubmed: 30089695
Hepatology. 2013 Oct;58(4):1225-35
pubmed: 23519785
J Virol. 2012 Jan;86(1):226-35
pubmed: 22013051
Nat Commun. 2014 Dec 15;5:5811
pubmed: 25503978
Sci Signal. 2012 Jul 17;5(233):ra50
pubmed: 22810896
MBio. 2019 Aug 20;10(4):null
pubmed: 31431555
Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5531-6
pubmed: 18375753
J Gen Virol. 2010 Feb;91(Pt 2):463-9
pubmed: 19864499
Antiviral Res. 2013 Nov;100(2):321-7
pubmed: 24070820
J Cell Physiol. 2002 Dec;193(3):287-92
pubmed: 12384981
Viruses. 2018 Aug 20;10(8):
pubmed: 30127257
Annu Rev Virol. 2016 Sep 29;3(1):333-357
pubmed: 27501258
J Gen Virol. 2009 Jul;90(Pt 7):1569-74
pubmed: 19321755
Cell Host Microbe. 2010 Oct 21;8(4):320-30
pubmed: 20951966
J Virol. 2009 Jun;83(11):5615-29
pubmed: 19297488
Cell. 1993 Jan 29;72(2):197-209
pubmed: 7678779
J Gen Virol. 2002 Nov;83(Pt 11):2803-10
pubmed: 12388817
Blood. 1995 Dec 1;86(11):4086-90
pubmed: 7492764
Cell Res. 2007 Jun;17(6):546-55
pubmed: 17502875
Blood. 2001 Mar 1;97(5):1298-305
pubmed: 11222373
J Virol. 2001 Jul;75(13):6022-32
pubmed: 11390604
Hematol Oncol Clin North Am. 2011 Feb;25(1):151-69
pubmed: 21236396
J Virol. 2003 Nov;77(22):12276-84
pubmed: 14581564
J Biol Chem. 2010 Nov 26;285(48):37491-502
pubmed: 20864524
J Virol. 2000 Nov;74(22):10838-45
pubmed: 11044134
Clin Microbiol Infect. 2008 Mar;14(3):221-7
pubmed: 18070129
EMBO J. 1995 Oct 2;14(19):4662-75
pubmed: 7588596
J Gen Virol. 2006 May;87(Pt 5):1139-44
pubmed: 16603514
J Biol Chem. 2010 Apr 2;285(14):10591-6
pubmed: 20123987
J Biol Chem. 1999 Feb 12;274(7):4400-11
pubmed: 9933644
Clin Infect Dis. 1992 Apr;14(4):831-5
pubmed: 1315585
Nat Rev Mol Cell Biol. 2011 Feb;12(2):104-17
pubmed: 21252999
J Virol. 2005 Sep;79(18):12095-9
pubmed: 16140786
J Virol. 2016 Jan 06;90(6):3138-47
pubmed: 26739047
PLoS Pathog. 2011 Dec;7(12):e1002444
pubmed: 22241980
J Virol. 2014 Dec;88(24):14412-25
pubmed: 25297993
PLoS Pathog. 2014 Jun 12;10(6):e1004195
pubmed: 24945302
J Virol. 2014 Jun;88(11):5987-6002
pubmed: 24623432
Methods Mol Biol. 2014;1119:99-112
pubmed: 24639220
J Virol. 2015 Dec 16;90(5):2356-71
pubmed: 26676786
PLoS One. 2012;7(3):e34515
pubmed: 22479638
Annu Rev Virol. 2016 Sep 29;3(1):215-236
pubmed: 27501260
Nucleic Acids Res. 2005 Feb 24;33(4):e36
pubmed: 15731329
J Virol. 2013 Oct;87(19):10763-76
pubmed: 23903834
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
J Virol. 2012 Aug;86(15):7771-6
pubmed: 22593153
Proc Natl Acad Sci U S A. 2015 May 5;112(18):5667-72
pubmed: 25825764
J Virol. 2013 Jul;87(14):8227-34
pubmed: 23698301
MBio. 2018 Mar 13;9(2):
pubmed: 29535194
J Virol. 2011 May;85(9):4399-408
pubmed: 21307189
Cell Host Microbe. 2015 Dec 9;18(6):649-58
pubmed: 26651941
Virology. 2016 Nov;498:31-35
pubmed: 27543756
MBio. 2017 Dec 5;8(6):null
pubmed: 29208743
Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10586-E10595
pubmed: 29158406
Blood. 1992 Jul 1;80(1):170-8
pubmed: 1377049
Am J Transplant. 2013 Mar;13 Suppl 4:93-106
pubmed: 23465003
J Virol. 2017 Nov 30;91(24):
pubmed: 29021395
J Clin Invest. 2011 May;121(5):1673-80
pubmed: 21659716
J Virol. 2006 Aug;80(15):7748-55
pubmed: 16840354
J Cell Physiol. 2009 Feb;218(2):294-303
pubmed: 18844239
J Mol Biochem. 2017;6(1):13-25
pubmed: 28491825
PLoS Pathog. 2016 May 24;12(5):e1005655
pubmed: 27218650
Blood. 2004 Aug 1;104(3):687-95
pubmed: 15090458
PLoS Pathog. 2019 Nov 14;15(11):e1007854
pubmed: 31725809
J Virol. 2010 Sep;84(18):9472-86
pubmed: 20592073
J Virol. 1995 Jul;69(7):4390-8
pubmed: 7769701
J Leukoc Biol. 2012 Oct;92(4):743-52
pubmed: 22715139
J Virol. 2011 Dec;85(23):12750-8
pubmed: 21937636
Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22369-74
pubmed: 20018733
J Gen Virol. 1996 Dec;77 ( Pt 12):3099-102
pubmed: 9000102
Cell Stem Cell. 2008 Apr 10;2(4):380-91
pubmed: 18397757
Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):588-93
pubmed: 22203987

Auteurs

Jason Buehler (J)

BIO5 Institute, University of Arizona, Tucson, Arizona, United States of America.

Ethan Carpenter (E)

BIO5 Institute, University of Arizona, Tucson, Arizona, United States of America.

Sebastian Zeltzer (S)

BIO5 Institute, University of Arizona, Tucson, Arizona, United States of America.

Suzu Igarashi (S)

BIO5 Institute, University of Arizona, Tucson, Arizona, United States of America.

Michael Rak (M)

BIO5 Institute, University of Arizona, Tucson, Arizona, United States of America.

Iliyana Mikell (I)

Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.

Jay A Nelson (JA)

Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.

Felicia Goodrum (F)

BIO5 Institute, University of Arizona, Tucson, Arizona, United States of America.
Department of Immunobiology, University of Arizona, Tucson, Arizona, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH